Ampio Pharmaceuticals (NYSE:AMPE) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Ampio Pharmaceuticals (NYSE:AMPEGet Free Report) in a note issued to investors on Sunday. The brokerage set a “sell” rating on the stock.

Ampio Pharmaceuticals Stock Performance

NYSE:AMPE opened at $0.14 on Friday. The stock has a 50-day simple moving average of $0.29 and a two-hundred day simple moving average of $1.24. Ampio Pharmaceuticals has a 52-week low of $0.13 and a 52-week high of $8.30. The firm has a market capitalization of $161,880.00, a PE ratio of -0.01 and a beta of 2.15.

Ampio Pharmaceuticals (NYSE:AMPEGet Free Report) last released its quarterly earnings results on Wednesday, March 27th. The company reported ($2.48) earnings per share (EPS) for the quarter.

About Ampio Pharmaceuticals

(Get Free Report)

Ampio Pharmaceuticals, Inc, a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.

Read More

Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.